KAZAN, Russian Federation,
March 31 /PRNewswire/ - Neuro-Biotech
Corp. (PinkSheets: MRES) (OTCQB: MRES) announces that following the
resumption of the buyout offer at $0.15 by AURIC Pharma Science, the Company will
proceed to the closing session on Tuesday
April 5 at its new corporate head office in Kazan,
Russian Federation.
Mr. Boris
Oleknovich, the Company new CEO and President commented: "We
figured this would be a perfect opportunity for the people at AURIC
and our shareholders to come and visit the new Neuro-Biotech head
office as well as get to know the new team steering the ship"
Neuro-Biotech Corp. filed and 8K to this effect
with the details about the new CEO and President Mr Boris Oleknovich as well as the address of the
new head office.
For more information on Neuro-Biotech Corp or to
contact a company representative, please visit:
www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Act of 1995. Certain statements in this press release
may contain words such as "anticipates," "believes," "could,"
"expects," "intends," "may," "projects," "targets" and other
similar language that is considered forward-looking statements.
These forward-looking statements are subject to certain risks and
uncertainties and persons reading this release are cautioned that
such statements are only predictions, and that the Company's actual
future results or performance may be materially different. The
Company disclaims any intention or obligation to update or revise
forward-looking information, whether as a result of new
information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
forward-looking statements.
SOURCE Neuro-Biotech Corp.
